Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Millions of prior authorization denials are made annually, leaving many patients stuck in a convoluted appeals process. For doctors, these decisions are frustrating. For patients, they can be ...